Patents by Inventor Jakob Lind Tolborg

Jakob Lind Tolborg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acylated glucagon analogues
    Patent number: 9896495
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: February 20, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9861706
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20170281709
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes related diseases or disorders.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 5, 2017
    Inventors: Trine Skovlund Ryge NEERUP, Torben ØSTERLUND, Jakob Lind TOLBORG, Keld FOSGERAU, Ulrika MARTENSSON, Marianne BRORSON, Kamilla ROLSTED
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9649362
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 16, 2017
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • GLUCAGON ANALOGUES
    Publication number: 20160347813
    Abstract: The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 1, 2016
    Inventors: Dieter Wolfgang HAMPRECHT, Jakob Lind TOLBORG, Ditte RIBER
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20160184400
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: June 10, 2015
    Publication date: June 30, 2016
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Martensson, Marianne Brorson, Kamilla Rolsted
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20160120951
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 2, 2015
    Publication date: May 5, 2016
    Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆk
  • GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES
    Publication number: 20160082118
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 24, 2016
    Inventors: Jakob Lind TOLBORG, Trine Skovlund Ryge NEERUP, Keld FOSGERAU, Torben ØSTERLUND, Dorthe Lennert Christensen ALMHOLT, Lone Frost LARSEN
  • GLP-1 receptor agonist peptide gastrin conjugates
    Patent number: 9259477
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: February 16, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Trine Skovlund Ryge Neerup, Keld Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • GLUCAGON ANALOGUES
    Publication number: 20160009777
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • Glucagon analogues
    Patent number: 9180169
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Acylated glucagon analogues
    Patent number: 9156901
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: October 13, 2015
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
    Patent number: 9089538
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 28, 2015
    Assignee: Zealand Pharma A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20150111826
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • GLUCAGON ANALOGUES
    Publication number: 20150111817
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT
  • GLP-1 RECEPTOR AGONIST PEPTIDE GASTRIN CONJUGATES
    Publication number: 20140336107
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: November 2, 2012
    Publication date: November 13, 2014
    Inventors: Jakob Lind Tolborg, Trine Neerup, Keid Fosgerau, Torben Østerlund, Dorthe Lennert Christensen Almholt, Lone Frost Larsen
  • GLUCAGON ANALOGUES
    Publication number: 20140080757
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 20, 2014
    Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/S
    Inventors: Jakob Lind TOLBORG, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas
  • GLUCAGON ANALOGUES
    Publication number: 20130316941
    Abstract: The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 19, 2012
    Publication date: November 28, 2013
    Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/S
    Inventors: Dieter Wolfgang Hamprecht, Jakob Lind Tolborg, Ditte Riber
  • PEPTIDE CONJUGATES OF GLP-1 RECEPTOR AGONISTS AND GASTRIN AND THEIR USE
    Publication number: 20130143793
    Abstract: The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 6, 2013
    Applicant: ZEALAND PHARMA A/S
    Inventors: Trine Skovlund Ryge Neerup, Torben Østerlund, Jakob Lind Tolborg, Keld Fosgerau, Ulrika Mårtensson, Marianne Brorson, Kamilla Rolsted
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20120178670
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 24, 2010
    Publication date: July 12, 2012
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk